GENFIT'S ASSETS FOR FUTURE VALUE CREATION

Genfit has put in place a dedicated organisation, which aims to create and preserve the intellectual assets for our development. Today, the company has a portfolio of 265 patents or patent applications regrouped into 29 families, each corresponding to a specific invention:

• Patents related to new molecules and their therapeutic usage, as well as new therapeutic usage for already known molecules,
• Patents related to dosage or diagnostic tools,
• Patents related to research methods and tools.

Our portfolio is regularly enriched by new patent applications which protect inventions resulting from in-house research.

A Selection of Genfit's Publications

A selection of Genfit's most recent publications is listed below. A complete list can be found here. 

• PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
  Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G.
  Cell Metab. 2007 Aug;6(2):96-8.
• Safety issues and prospects for future generations of PPAR modulator
  Anne Rubenstrunk, Rémy Hanf, Dean W. Hum, Jean-Charles Fruchart, Bart Staels
  Biochimica et Biophysica Acta 1771 (2007) 1065–1081
• Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
  Fruchart JC and Duriez P
  Drugs Today (Barc), 2006, 42 (1), 39-64
• Sorting out the roles of PPARa in energy metabolism and vascular homeostasis
  Lefebvre P, Chinetti G, Fruchart JC and Staels B
  The Journal of Clinical Investigation, 2006, 116 (3), 571-581
• The Neuroprotective Effect of Atorvastatin in a Murine MCAO Model Is Dependent on PPARalpha
  Sayah-Jeanne S, Bordet R, Laprais M, Poulain P, Coussaert A, Duriez P, Hanf R, Laskey R, Sasiela W, Hum D, Staels B and Fruchart JC
  Stroke. 2006 Feb. 37(2)732, 2006, 37 (2), 732
• Pro-inflammatory cytokines IL-1, TNFa and IL-6 stimulate apolipoprotein A5 gene expression in mice through transactivation of a NF-KB p50 response element
  Genoux A, Helleboid-Chapman A, Dehondt H, Bauge E, Niculescu LS, Hum DW, Nowaka M, Jakel H, Martin G, Fruchart-Najib J and Fruchart JC
  3rd Metabolic syndrome, Type II diabetes and Atherosclerosis congress, Marrakesh, May 24-28th 2006
• Transcriptional regulation of Apolipoprotein A5 gene expression by glucose through protein phosphatases signallingpathway and USF
  Nowak M, Helleboid-Chapman A, Jakel H, Moitrot E, Martin G, Pennacchio LA, Fruchart-Najib J and Fruchart JC
  3rd Metabolic syndrome, Type II diabetes and Atherosclerosis congress, Marrakesh, May 24-28th 2006
• Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy
  Chinetti-Gbaguidi G, Fruchart JC and Staels B
  Curr Opin Pharmacol, 2005, 5 (2), 177-83
• Peroxisome Proliferator-Activated Receptor b/d: A novel target for the reduction of atherosclerosis
  Gross BS, Fruchart JC and Staels B
  Drug Discovery Today: Therapeutic Strategies, 2005, 2 (3), 237-243
• Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation
  Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fievet C, Lefebvre P and Staels B
  Arterioscler Thromb Vasc Biol, 2005, 25 (3), 585-91
• TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1
  Gizard F, Robillard R, Barbier O, Quatannens B, Faucompre A, Revillion F, Peyrat JP, Staels B and Hum DW
  Mol Cell Biol, 2005, 25 (11), 4335-48
• Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor
  Nowak M, Helleboid-Chapman A, Jakel H, Martin G, Duran-Sandoval D, Staels B, Rubin EM, Pennacchio LA, Taskinen MR, Fruchart-Najib J and Fruchart JC
  Mol Cell Biol, 2005, 25 (4), 1537-48
• Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene
  Gizard F, Robillard R, Gervois P, Faucompre A, Revillion F, Peyrat JP, Hum WD and Staels B
  FEBS Lett, 2005, 579 (25), 5535-41
• Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity
  Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B and Kintscher U
  Diabetes, 2005, 54 (12), 3442-52
• PPARgamma activating angiotensin receptor blockers exhibit differential cofactor recruitment and induce a divergent gene expression profile in 3T3-L1 adipocytes
  Schupp M, Gineste R, Clemenz M, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B and Kintscher U
  3rd International Symposium on PPARs efficacy and safety - Abstract book, 2005
• Farnesoid X receptor represses hepatic lipase gene expression
  Sirvent A, Verhoeven AJ, Jansen H, Kosykh V, Darteil RJ, Hum DW, Fruchart JC and Staels B
  J Lipid Res, 2004, 45 (11), 2110-5
• The farnesoid X receptor induces very low density lipoprotein receptor gene expression
  Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R, Hum DW, Fruchart JC and Staels B
  FEBS Lett, 2004, 566 (1-3), 173-7
• The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c
  Jakel H, Nowak M, Moitrot E, Dehondt H, Hum DW, Pennacchio LA, Fruchart-Najib J and Fruchart JC
  J Biol Chem, 2004, 279 (44), 45462-9
• Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe
  Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL, Guillaume M, Maxwell SE and Veltri EP
  Curr Med Res Opin, 2004, 20 (8), 1197-207
• Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
  Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA and Fruchart JC
  Biochem Biophys Res Commun, 2004, 319 (2), 397-404
• PPARs--second international symposium. From basic science to clinical applications. 19-22 March 2003, Florence, Italy
  Gomaraschi M
  IDrugs, 2003, 6 (5), 429-31

Bouhlel, AM, Derudas, B, Rigamonti, E, Dievart, R, Brozek, J, Haulon, S, Zawadzki, C, Jude, B, Torpier, G, Marx, N, Staels, B, Chinetti-Gbaguidi, G Cell Metab. 2007 Aug;6(2):96-8.

Other Publications